b1banpc-873.jpg b1banph-303.jpg



YolTech Therapeutics is a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies. The company has built a leading high-throughput evolution platform and innovative LNP delivery system. YolTech possesses a strong capability for novel Cas and base editor discovery, as well as exceptional in-house LNP production capacity for GMP manufacturing. It holds independent intellectual property rights and core patent protection globally. The company has created a pipeline of 10 genetic medicines focusing on cardiovascular diseases, metabolic diseases, infectious diseases, as well as more common and rare diseases. Clinical trial clearance has been received for its leading asset in March 2024.

  • 50

    Research Personnel

  • 40

    Published Papers

  • 10

    Doctoral Talent


  • 2024
    • April

      First Patient Dosed in Clinical Trial of YOLT-101

    • June

      Phase I Clinical Trial of YOLT-201

  • 2024
    • Jan

      New Members to SAB Appointed

    • Feb

      Base Editor Patent Granted

    • Mar

      YOLT-201 IND Application Approved

    • Apr

      CRISPR/Cas Patent Granted

  • 2023
    • Mar

      GMP Manufacture Site Established

    • Jun

      Novel Lipid Patent Granted

    • Jun

      YOLT-201 GLP Tox Study Completed

      Pre-IND submitted

    • Nov

      Series A+ Financing

    • Dec

      IND for leading Asset

      Estimated to have IIT data and IND filing

  • 2022
    • Feb

      Shanghai R&D Center Established

    • Apr

      Novel Base Editor Patent Filed

    • Jun

      Series A Financing

    • Jul

      Novel CRISPR/Cas Patent Filed

    • Aug

      Preclinical POC in NHP

      Durable PCSK9 reduction in NHPs after single dose i.v.

  • 2021
    • Jul

      Company Establishment

    • Sep

      Angel Round Financing

  • b1img2024.jpg
  • b1_img2024.jpg
  • b1_img2023.jpg
  • b1_img2022.jpg
  • b1_img2021.jpg